
Releases
Simcere Pharmaceutical Partners with Stanford to Combat Pulmonary Fibrosis
Simcere Pharmaceutical has signed a research agreement with Stanford Medicine to develop novel therapies for idiopathic pulmonary fibrosis. The collaboration targets a first-in-class molecule, granting the Shanghai-based company full global rights to the resulting product upon successful completion of exploratory research conducted by Stanford’s chemical biology laboratories.























